Comparison
BPC-157 vs. Lixisenatide
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Healing
Metabolic
CAS no.
137525-51-0
320367-13-3
Molecular weight
1419.5 g/mol
4858.5 g/mol
Half-life
4 h
3 h
Sequence
GEPPPGKPADDAGLVHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2Mechanism of action
BPC-157
Synthetic peptide derived from a sequence of a protein found in gastric juice. In preclinical models, an influence on angiogenic and tissue-protective signalling pathways has been described. The precise molecular mechanisms of action are not conclusively understood.
Lixisenatide
Lixisenatide is a 44-amino-acid peptide based on exendin-4 (see exenatide) with six additional lysine residues at the C-terminus. This modification increases stability against DPP-4 degradation. The short half-life (~3 hours) and plasma peak around mealtime explain the predominantly prandial effect — stronger postprandial glucose action, weaker fasting glucose effect than weekly GLP-1 RAs.
Evidence base
Highest evidence
Animal model
Human RCT
Studies
4
5
of which in humans
0
5
Effects recorded
4
3
Open conflicts
2
1
Documented adverse events
2
1